TG Therapeutics (TGTX) Stock Price, Quote, News & History | Benzinga

TG Therapeutics Inc (TGTX) Stock Price, Quote, News & History

TGTXNASDAQ

Trade with Public

Trade with Public

$48.74

0.801.67%

At close: Aug 14, 5:00 PM EST

$48.50

-0.24-0.49%

After Hours: 6:14 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$47.27

Close

$48.74

Volume / Avg.

1.07M / 2.37M

Day Range

$47.27 - $48.93

52 Wk Range

26.76 - 59.30

Market Cap

$7.42B

P/E Ratio

17.50

Dividend Yield

-

Exchange

NASDAQ

RSI

41

Short Interest

27.68%

Days to Cover

13.62

Recent TG Therapeutics, Inc. News

TG Therapeutics Stock Rises Thursday: What's Driving The Gains?

TG Therapeutics shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.

Henry Khederian

Top 3 Health Care Stocks That May Collapse This Quarter

3 health care stocks flashing warning: CAH RSI 77.7, TGTX RSI 79.8, AMRX RSI 76.9; all overbought, but positive price action for TGTX.

Avi Kapoor

TG Therapeutics Stock Is Surging Today: What's Driving The Action?

TG Therapeutics shares are trading higher on Wednesday as positive topline Phase 1 data fuels fresh optimism around pipeline expansion.

Henry Khederian

Caseys General Stores Upbeat Q4 Earnings, Joins Applied Optoelectronics, Clover Health Investments And Other Big Stocks Moving Higher On Wednesday

US stocks down, Dow Jones fell 150 pts on Wed. Caseys General Stores Inc (CASY) shares up 14.4% after beating earnings. Other big gainers incl. CBRL, PLBL, RXT, YB, AXTI, AAOI, LMND, CLOV, TGTX, CRDO, CBRS, HOOD, FLNC, LITE, TTMI

Avi Kapoor

Why Is TG Therapeutics Stock Gaining Tuesday?

TGTX stock rises on positive Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis. See what's next for TG Therapeutics.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

17.88M

Investing Cash Flow (TTM)

21.89M

Financing Cash Flow (TTM)

313.73M

Free Cash Flow (TTM)

17.39M

Capital Expenditure (TTM)

-491.00K

Net Change in Cash (TTM)

353.50M

Analyst Trends and Forecast

2

May

3

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.5

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$7.67B

PE Ratio (TTM)

17.50

PE Ratio (FWD)

59.17

PEG Ratio (TTM)

-

PS Ratio (TTM)

9.56

PB Ratio (TTM)

12.15

Earnings Yield % (TTM)

5.72%

Earnings Yield % (FWD)

1.69%

EV / EBITDA (TTM)

54.09

Price / EBITDA (TTM)

54.85

Price / Free Cash Flow (TTM)

439.78

Book Value / Share

$3.95

Company Debt

Total Debt

$745.39M

LT Debt

$745.39M

LT Debt Issuance (TTM)

$747.66M

LT Debt Repayment (TTM)

-$255.00M

Total Cash

$482.58M

Debt to Equity

1.25

Issuance of Debt (TTM)

$492.66M

Repayment of Debt (TTM)

-$255.00M

Key Statistics

Open

$47.27

Close

$48.74

Volume / Avg.

1.07M / 2.37M

Day Range

$47.27 - $48.93

52 Wk Range

26.76 - 59.30

Market Cap

$7.42B

P/E Ratio

17.50

Dividend Yield

-

Exchange

NASDAQ

RSI

41

Short Interest

27.68%

Days to Cover

13.62

About

Sector

Health Care

Industry

Biotechnology

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval fr...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy TG Therapeutics (TGTX) stock?

A

You can purchase shares of TG Therapeutics (NASDAQ:TGTX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are TG Therapeutics (TGTX) competitors?

A

Other companies in TG Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for TG Therapeutics (TGTX) stock?

A

TG Therapeutics has a consensus price target of $51.36.

Q

What is the current price for TG Therapeutics (TGTX)?

A

The stock price for TG Therapeutics (NASDAQ: TGTX) is $48.5 last updated August 14, 2026 at 6:14 PM EDT.

Q

Does TG Therapeutics (TGTX) pay a dividend?

A

There are no upcoming dividends for TG Therapeutics.

Q

When is TG Therapeutics (NASDAQ:TGTX) reporting earnings?

A

TG Therapeutics does not have any upcoming earnings scheduled.

Q

Is TG Therapeutics (TGTX) going to split?

A

There is no upcoming split for TG Therapeutics.

Q

What sector and industry does TG Therapeutics (TGTX) operate in?

A

TG Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.